Enjoy complimentary customisation on priority with our Enterprise License!
The narcolepsy drugs market size is forecast to increase by USD 1.81 billion at a CAGR of 10.03% between 2023 and 2028.
The narcolepsy drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Narcolepsy with cataplexy, a rare and debilitating sleep disorder, affects approximately 20-30 individuals per 100,000 globally. Characterized by sudden muscle weakness (cataplexy) and excessive daytime sleepiness, this condition is typically diagnosed during adolescence or young adulthood and persists throughout the lifespan. The underlying cause is the loss of hypocretin-producing neurons In the hypothalamus, a neurotransmitter associated with wakefulness. Other symptoms include hallucinations, sleep paralysis, disrupted night-time sleep, and weight gain. The aging population and increased stress levels contribute to the rise in healthcare expenditure for treating narcoleptic diseases. Central hypersomnia, circadian delay, and obesity rates further complicate the condition. Various treatments, including psychostimulants, tricyclic antidepressants, sodium oxybate, and medications like modafinil, antiepileptics, and psychiatric medications, are available.
The reimbursement environment varies, and access to medical infrastructure, such as hospitals and diagnostic centers, is crucial for proper diagnosis and treatment. Narcolepsy, a chronic problem influenced by lifestyle factors like stress, addictive substances, and sleep interruptions, necessitates ongoing medical care and drug development.
Get a glance at the Narcolepsy Drugs Industry report of share of various segments Request Free Sample
The Narcolepsy with cataplexy segment was valued at USD 1.31 billion in 2018 and showed a gradual increase during the forecast period.
Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The North American market holds the largest share In the market due to high healthcare expenditure, advanced medical infrastructure, and the presence of major market players. In the US and Canada, the prevalence of narcolepsy, stress levels, and aging population contribute significantly to the market growth. New treatments, such as pitolisant, solriamfetol, and Xywav, targeting narcolepsy disorder, central hypersomnia, circadian delay, and cataplexy, have been introduced, further fueling the market expansion. The reimbursement environment and accessibility to diagnostic centers, hospitals, polysomnography, and other medical facilities facilitate the treatment of daytime extreme sleepiness, sleep attacks, and sleepiness. Obesity rates, addictive substances like alcohol and tobacco, and sleep interruptions are chronic problems exacerbating the need for medications and lifestyle changes.
The market is expected to grow due to ongoing drug development, medical care advancements, and the increasing awareness of sleep disorders.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising product launches and clinical trials is the key driver of the market.
Advancement in narcolepsy treatment is the upcoming market trend.
What challenges does the Narcolepsy Drugs Industry face during its growth?
Lack of awareness is a key challenge affecting the industry growth.
Exclusive Customer Landscape
The narcolepsy drugs market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the narcolepsy drugs market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, narcolepsy drugs market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.
Alkermes Public Ltd. Co. - The company specializes In the development and commercialization of treatments for various neurological conditions, including narcolepsy. Among its offerings are ALKS 2680 tablets, a medication utilized for managing the symptoms of this chronic disorder characterized by excessive daytime sleepiness and sudden, uncontrollable episodes of sleep. This medication, which functions as a selective and reversible orexin receptor antagonist, aims to help improve wakefulness and reduce sleep attacks in affected individuals. By addressing the underlying neurological mechanisms of narcolepsy, the company's therapeutic solutions contribute to enhancing the quality of life for those diagnosed with this condition.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Narcolepsy, a chronic sleep disorder characterized by daytime extreme sleepiness and sudden, uncontrollable episodes of sleep, affects a significant portion of the adult population. This condition, which can also include symptoms such as cataplexy, sleep attacks, and sleep paralysis, poses a significant challenge for those afflicted and places a burden on the healthcare system. The aging population is a key demographic In the context of narcolepsy. As people grow older, they become more susceptible to various health conditions, including sleep disorders. Stress levels, which are known to exacerbate the symptoms of narcolepsy, are also more prevalent in older adults due to various factors such as work pressures and personal responsibilities.
The healthcare expenditure related to the management of narcolepsy and other sleep disorders is substantial. The medical infrastructure required to diagnose and treat these conditions includes hospitals, diagnostic centers, and specialized sleep disorder clinics. Polysomnography, a diagnostic test used to identify sleep disorders, is a critical component of this infrastructure. Central hypersomnia, a condition characterized by excessive daytime sleepiness, is closely related to narcolepsy. Circadian delay, a disruption In the normal sleep-wake cycles, is another common issue that can contribute to daytime sleepiness. Both of these conditions can be managed through a combination of medications and lifestyle changes.
The reimbursement environment for narcolepsy treatments is an important consideration for patients and healthcare providers alike. Psychiatric medications, antiepileptics, and stimulants are among the classes of drugs commonly used to manage the symptoms of narcolepsy. Sodium oxybate, a medication that has shown significant efficacy In the treatment of narcolepsy with cataplexy, is an example of a specialized therapy that may require special reimbursement considerations. Obesity rates, addictive substances such as alcohol and tobacco, and other lifestyle factors can also impact the prevalence and severity of narcolepsy. These factors can contribute to the development of sleep disorders and exacerbate the symptoms of existing conditions.
Drug development for narcolepsy and other sleep disorders is an active area of research. New treatments and therapies are being explored to address the underlying causes of these conditions and improve the quality of life for those affected. Medical care for narcolepsy and other sleep disorders requires a multidisciplinary approach, involving collaboration between healthcare providers, patients, and researchers. The brain's sleep-wake cycles are regulated by a complex system of chemicals, including orexin and hypocretin. Disruptions to this system can lead to conditions such as narcolepsy. Brain tumors and other neurological conditions can also contribute to sleep disorders. The overweight populace and peer pressure are additional factors that can impact the prevalence and management of sleep disorders.
Personal protective equipment, such as face masks, gloves, and eye protection, can help mitigate the risk of respiratory distress syndrome and other health issues related to sleep disorders. In conclusion, the market for narcolepsy drugs is driven by the growing prevalence of sleep disorders, the aging population, and the need for effective treatments. The complex nature of these conditions requires a multidisciplinary approach to diagnosis, treatment, and management. Ongoing research and innovation In the field of sleep medicine offer hope for those affected by narcolepsy and other sleep disorders.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
133 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
|
Market growth 2024-2028 |
USD 1806.6 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.88 |
|
Key countries |
US, Germany, UK, Canada, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
We can help! Our analysts can customize this narcolepsy drugs market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
